Floatz logo

Vy-Aadc01

Movement Disorders

Neurocrine Biosciencesgene_therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Movement Disorders cohort.

Asset / SponsorPhaseRating
LEVODOPA
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BBB
TRIMETHOBENZAMIDE
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BB
APOMORPHINUM
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BB
LEMBOREXANT
YangPan
Phase 4BB

View all 24 →

Same molecule, other indications

Vy-Aadc01 is also rated in:

Parkinson diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
basal ganglia disorderDormant
CC
Indicative ·
47 / 100
View asset →
neurodegenerative diseaseDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →